Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.

Saved in:
Bibliographic Details
Title: Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
Authors: Bancroft EK; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK., Saya S; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK., Page EC; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK., Myhill K; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK., Thomas S; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK., Pope J; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK., Chamberlain A; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK., Hart R; Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham, UK., Glover W; Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham, UK., Cook J; Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK., Rosario DJ; Department of Urology, Royal Hallamshire Hospital, Sheffield, UK., Helfand BT; John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA., Hutten Selkirk C; John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA., Davidson R; Clinical Genetics Department, Queen Elizabeth University Hospital, Glasgow, UK., Longmuir M; Clinical Genetics Department, Queen Elizabeth University Hospital, Glasgow, UK., Eccles DM; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.; Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Gadea N; High Risk and Cancer Prevention Clinic, Vall d'Hebron University Hospital, Barcelona, Spain., Brewer C; Clinical Genetics Department, Royal Devon and Exeter Hospital, Exeter, UK., Barwell J; Department of Genetics, University of Leicester, Leicester, UK.; Clinical Genetics, University Hospitals Leicester, Leicester, UK., Salinas M; Hereditary Cancer Programme, Catalan Institute of Oncology (ICO-IDIBELL, CIBERONC), L'Hospitalet de Llobregat, Barcelona, Spain., Greenhalgh L; Cheshire and Mersey Clinical Genetics Service, Liverpool Women's Hospital, Liverpool, UK., Tischkowitz M; Academic Department of Medical Genetics, University of Cambridge, Cambridge, UK., Henderson A; Northern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle, UK., Evans DG; Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK., Buys SS; Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, USA., Eeles RA; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK., Aaronson NK; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Corporate Authors: IMPACT Study Steering Committee, IMPACT Collaborators
Source: BJU international [BJU Int] 2019 Feb; Vol. 123 (2), pp. 284-292. Date of Electronic Publication: 2018 Jun 22.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-410X (Electronic) Linking ISSN: 14644096 NLM ISO Abbreviation: BJU Int Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1464-410X
DOI:10.1111/bju.14412